Under the agreement, Zealand will contribute its expertise in peptide drug discovery to Iktos’ generative modelling technologies and expertise in machine learning and AI.
“We are very pleased to join forces with Zealand Pharma and leverage their deep know-how in peptide therapeutics with our state-of-the-art existing technology assets to peptide drug discovery,” says Yann Gaston-Mathé, President and CEO of Iktos. “We look forward to working with Zealand’s experienced R&D team to build leading/state of the art peptide generative and predictive modelling technology in the field of peptides – a new area for Iktos.”
“We are very pleased to join forces with Zealand Pharma and leverage their deep know-how in peptide therapeutics with our state-of-the-art existing technology assets to peptide drug discovery”
Iktos’ AI technology automatically designs virtual novel molecules with all the characteristics of a successful drug molecule, states the company. Iktos has recently diversified its R&D efforts into the development of an AI technology for peptide-based therapeutics and has developed generative and predictive models to facilitate design of novel peptide therapeutics with desired properties.
Zealand Pharma has a invented and developed novel peptide-based drugs. This success is based on the extensive experience in improving the therapeutic characteristics of peptides. Zealand Pharma has a keen interest in expanding its computational chemistry toolbox to include AI and machine learning based approaches for the design of novel therapeutic peptides, it states.
Photo: Zealand Pharma